← ANALYST RATINGS · TIPRANKS
Bruker (BRKR): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy4 Hold1 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $62.12, the highest $80.00, the lowest $50.00. The average is +13.4% from the last price of $54.80.
Analyst ratings 20
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $60.00 | Hold | +9.5% | Downgrade | 13.10.26on TipRanks Oct 14 06:00 | −0.1%next day 0.0% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $60.00 → $62.00+3.3% | Hold | +13.1% | Reiterated | 13.10.26on TipRanks 08:41 | −0.1%next day 0.0% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $58.00 → $70.00+20.7% | Buy | +27.7% | Reiterated | 07.10.26on TipRanks 03:55 | −1.0%next day −2.6% · 5 days −5.9% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $67.00 → $66.00−1.5% | Hold | +20.4% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $66.00 → $65.00−1.5% | Hold | +18.6% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $63.00 → $62.00−1.6% | Hold | +13.1% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $67.00 → $66.00−1.5% | Hold | +20.4% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| Unknown Analyst | Goldman Sachs | $40.00 → $50.00+25.0% | Sell | −8.8% | Reiterated | 05.10.26on TipRanks Oct 6 23:05 | +0.3%next day −5.8% · 5 days −12.3% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $70.00 → $72.00+2.9% | Buy | +31.4% | Reiterated | 01.10.26on TipRanks 08:30 | −4.5%next day +1.4% · 5 days −7.8% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $66.00 → $67.00+1.5% | Hold | +22.3% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $66.00 | Hold | +20.4% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $67.00 | Hold | +22.3% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $63.00 | Hold | +15.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $67.00 | Hold | +22.3% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $59.00 → $66.00+11.9% | Hold | +20.4% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | $60.00 → $80.00+33.3% | Buy | +46.0% | Reiterated | 29.09.26on TipRanks 08:55 | +2.1%next day +0.6% · 5 days −8.2% | ↗ |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $40.00 → $50.00+25.0% | Sell | −8.8% | Reiterated | 20.09.26on TipRanks Sep 22 21:11 | −1.2%next day −0.6% · 5 days +3.8% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $58.00 | Buy | +5.8% | Reiterated | 25.08.26on TipRanks 04:27 | −0.5%next day +0.3% · 5 days −0.9% | ↗ |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $65.00 → $60.00−7.7% | Buy | +9.5% | Reiterated | 06.08.26on TipRanks Aug 7 08:10 | −2.1%next day +3.6% · 5 days +11.8% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | — | Buy | — | Reiterated | 05.08.26on TipRanks 13:25 | +4.5%next day −2.1% · 5 days +12.6% | ↗ |
| Unknown Analyst | Wells Fargo | $55.00 | Buy | +0.4% | Reiterated | 05.08.26on TipRanks 08:01 | +4.5%next day −2.1% · 5 days +12.6% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $45.00 → $50.00+11.1% | Hold | −8.8% | Reiterated | 05.08.26on TipRanks 07:15 | +4.5%next day −2.1% · 5 days +12.6% | ↗ |
| Patrick B Donnelly★★★★★★★★★★#2106 · hits 54% · avg +6.0% | Citi | $60.00 → $53.00−11.7% | Hold | −3.3% | Reiterated | 05.08.26on TipRanks 06:40 | +4.5%next day −2.1% · 5 days +12.6% | ↗ |
| Kyle Boucher★★★★★★★★★★#3152 · hits 100% · avg +25.0% | TD Cowen | $60.00 | Hold | +9.5% | Reiterated | 04.08.26on TipRanks Aug 5 02:55 | −23.6%next day +4.5% · 5 days +13.5% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | — | Hold | — | Downgrade | 01.06.26on TipRanks 16:15 | −2.1%next day +10.1% · 5 days +2.8% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $40.00 → $45.00+12.5% | Hold | −17.9% | Assigned | 07.05.26on TipRanks 07:55 | +3.7%next day +0.2% · 5 days −1.3% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $55.00 → $50.00−9.1% | Buy | −8.8% | Reiterated | 12.02.26on TipRanks 14:30 | −10.0%next day −2.7% · 5 days +0.9% | ↗ |
| Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% | Wolfe Research | $60.00 | Buy | +9.5% | Upgrade | 10.12.25on TipRanks 09:00 | +2.8%next day −1.4% · 5 days −3.0% | ↗ |
| Natalya Davies★★★★★★★★★★#4625 · hits 89% · avg +16.4% | Rothschild & Co Redburn | $60.00 | Buy | +9.5% | Reiterated | 20.11.25on TipRanks Nov 21 03:45 | +2.6%next day +6.8% · 5 days +6.6% | ↗ |
| Jack Meehan★★★★★★★★★★#787 · hits 68% · avg +14.4% | Nephron | — | Hold | — | Upgrade | 03.11.25on TipRanks 17:25 | +5.5%next day −0.8% · 5 days +2.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Bruker
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $59.78 at a price of $64.75 (−7.7%); now: $61.33 at $54.80 (+11.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 6 | 7 | 6 | 9 | 6 | 8 |
| Hold | 5 | 6 | 7 | 6 | 6 | 6 |
| Sell | 0 | 0 | 2 | 2 | 3 | 2 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.42 (from $0.39 to $0.45). Last quarter: $0.49.
Sales
Next quarter’s sales estimate — $865M (from $849M to $871M). Last quarter: $838M.
Best top-analyst consensus in the sector · Healthcare
About Bruker
- CEO: Frank H. Laukien
- Employees: 11,085
- 40 Manning Road, Billerica, MA, 01821, US
- www.bruker.com
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflec
Data from the stock’s TipRanks forecast page, read 55 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗